Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRIME-HCC: Preliminary Assessment of Safety and Bioactivity of the Ipilimumab and Nivolumab Combination Prior to Liver Resection (LR) in Hepatocellular Carcinoma (HCC)

Next Previous
Trial Profile

PRIME-HCC: Preliminary Assessment of Safety and Bioactivity of the Ipilimumab and Nivolumab Combination Prior to Liver Resection (LR) in Hepatocellular Carcinoma (HCC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms PRIME-HCC

Most Recent Events

  • 06 Jun 2023 Results ( As of 7th of February 2023, n=25 ) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 12 Dec 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2023.
  • 12 Dec 2022 Planned primary completion date changed from 31 Dec 2021 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top